Please login to the form below

Not currently logged in

Novo Nordisk resumes Greek insulin supplies

Novo Nordisk will resume supplying its modern insulin products to Greece after the country agreed to raise prices following mandatory price cuts

Novo Nordisk will resume supplying its modern insulin products to Greece after the country agreed to raise its prices on the drugs following mandatory price cuts earlier in the year.

The Danish company, which is the world's biggest maker of insulin, said in an emailed statement that Greece issued a new price bulletin, effective from June 14, for 48 insulin products including Novo Nordisk's modern insulins and pen-based insulins.

The new prices are higher than those dictated by the decree which took effect on May 3, but lower than the average of the three lowest prices in Europe.

Novo Nordisk has deemed this reasonable because "the government has stated it will base future prices in Greece on the average of the three lowest prices in Europe in an upcoming price decree."

"We have therefore accepted the new temporary prices," a company spokesman added. "As a result, we expect that all pharmacies will soon be able to deliver the full range of Novo Nordisk insulin products in Greece."

Novo Nordisk withdrew some of its products from Greece in May after the country's government introduced a mandatory drug price cut of around 25 per cent, which the drugmaker called "unacceptable".

The authorities plan to implement the new drug-pricing scheme by September 1, 2010.

15th June 2010


Featured jobs

Subscribe to our email news alerts


Add my company

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...